Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

0%

0 of 20 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(50.0%)
N/A
3(50.0%)
6Total
Phase 4(3)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07461233Not ApplicableNot Yet Recruiting

Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients

Role: lead

NCT07443280Not ApplicableNot Yet Recruiting

Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic

Role: lead

NCT06206694Completed

Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients

Role: lead

NCT06877585Recruiting

Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels

Role: lead

NCT06211244Completed

Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients

Role: lead

NCT05752968Completed

Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease

Role: lead

NCT04639674Phase 4Completed

AST-120 in Hemodialysis Patients With Uremic Pruritus

Role: collaborator

NCT05256004Completed

Cardiac Biomarkers and Iron Status in Hemodialysis Patients

Role: lead

NCT03427307Completed

Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients

Role: lead

NCT04309019Completed

Constipation, Gut Microbiome, and Microbial-derived Uremic Toxins From the Gut Microbiota in HD Patients

Role: lead

NCT04735562Completed

Thrombospondin-4 Levels and Peripheral Arterial Disease in Hemodialysis Patients

Role: lead

NCT04868318Not ApplicableCompleted

The Impact of Intervention With High-protein Enteral Formula in SICU.

Role: lead

NCT03925753Completed

Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients

Role: lead

NCT04307121Completed

Association of Constipation Inflammatory and Microbial Translocation Markers

Role: lead

NCT04309201Completed

Insulin Resistance, Sarcopenia and Plasma BAIBA Levels

Role: lead

NCT03929458Completed

Association of Uremic Sarcopenia and Mitochondrial Copy Number and Its Clinical Correlates

Role: lead

NCT03060590Completed

Roles of Uremic Toxins in Uremic Sacropenia

Role: lead

NCT03288285Completed

Comparison of Post- and Pre-dilutional Hemodiafiltration in Hemodialysis Patients

Role: lead

NCT02799719Completed

Body Fat Mass Association With Clinical Metabolic Profiles, Markers of Inflammation and Adipocytokines

Role: lead

NCT02718612Completed

Prevalence and Determinants of Sarcopenic Obesity in Taiwanese Dialysis Patients

Role: lead